Enzolytics, Inc.

ENZC

US2941121079

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 20:29:56 22/05/2024 BST			5-day change	1st Jan Change
0.00364 ^USD	+10.30%		-2.70%	-79.43%

05-02	Enzolytics, Inc. Announces Formation of Marketing Company in Partnership with Third Coast Fulfillment LLC	CI
03-25	Enzolytics, Inc. Announces Board Changes	CI

Enzolytics Inc. announced that it has received $0.25 million in funding

November 09, 2020

Enzolytics Inc. (OTCPK:ENZC) announced $250,000 in funding on November 10, 2020. The company expected to raise $500,000 in the transaction in two tranches.

Latest news about Enzolytics, Inc.

Enzolytics, Inc. Announces Formation of Marketing Company in Partnership with Third Coast Fulfillment LLC	05-02	CI
Enzolytics, Inc. Announces Board Changes	03-25	CI
Enzolytics, Inc Appoints Diana Zhabilov as Chief Financial Officer	03-25	CI
Enzolytics, Inc Appoints Steven Sharabura as Chief Executive Officer	03-25	CI
Enzolytics Offers Update on Virogentics, Inc ITV-1 African Project	26/06/23	CI
Enzolytics, Inc. Provides Update on Clinical Trials	21/04/23	CI
Biogenysis, Inc. & Virogentics, Inc. executed a non-binding term sheet to acquire Sagaliam Acquisition Corp. from Lighthouse Investment Partners, LLC, Enzolytics, Inc., Sagaliam Sponsor LLC, GLD Sponsor Member, LLC, AHG Equities LLC and others for $450 million in a reverse merger transaction.	16/04/23	CI
Enzolytics Announces Preliminary Results of GLP Toxicology Study for its anti-HIV Therapeutic ITV-1 and Production of ITV-1 for Initiation of Registration in Africa	08/02/23	CI
Enzolytics to Develop Feline Monoclonal Antibodies	03/01/23	CI
Enzolytics, Inc. Announces U.S. Distribution of IPF Immune(TM) and Progress in each of its Therapeutic Platforms	13/12/22	CI
Enzolytics, Inc. Announces Expansion of Production of Its Monoclonal Antibody Therapeutics and Marketing of IPF Immune	16/11/22	CI
Enzolytics, Inc. Appoints Dr. Kirsten Bischof to Its Advisory Board	24/10/22	CI
Enzolytics Inc. Reports Successful Completion of an MTD Tolerability Study of Its ITV-1 anti-HIV Therapeutic Leading to the Start of a 28-day GLP Toxicology Study	05/10/22	CI
Enzolytics Inc. Announces Collaboration with Abveris to Discover Monoclonal Antibodies	16/09/22	CI
Enzolytics Inc. and Samsung Biologics Co., Ltd. Announce Development and Manufacturing Agreement	07/10/21	CI
Enzolytics Inc. completed the acquisition of BioClonetics Immunotherapeutics, Inc.	30/11/20	CI
Enzolytics, Inc. Announces Appointment of Ronald Moss to the Medical Advisory Board	10/11/20	CI
Enzolytics Inc. announced that it has received $0.25 million in funding	09/11/20	CI
Enzolytics Inc. Announces the Appointment of Charles Cotropia as CEO	22/10/20	CI
Enzolytics Inc. Appoints Harry Zhabilov as CSO	22/10/20	CI
Enzolytics Inc. executed a non-binding letter of intent to acquire BioClonetics Immunotherapeutics, Inc.	15/09/20	CI
Eco-Petroleum Solutions, Inc. will Change its Name to Enzolytics Inc	22/03/18	CI
Enzolytics Inc. will Change its Ticker to ENZC from ECPO	22/03/18	CI
Eco Petroleum Solutions, Inc. Announces Exclusive Distribution Agreement with IMMB BG	22/06/17	CI
Eco-Petroleum Solutions, Inc. acquired Immunotech Laboratories, Inc..	13/06/17	CI

Enzolytics, Inc. is a drug development company. The Company is engaged in the commercialization of its proteins and monoclonal antibodies for the treatment of debilitating infectious diseases. Its patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF) for the treatment of human immunodeficiency virus/ acquired immunodeficiency syndrome (HIV/AIDS). It has a technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases which is being employed to produce monoclonal antibody therapeutics for treating the Coronavirus (SARS-CoV-2), HIV-1 and the Feline Leukemia virus. The Company also plans to produce mAbs targeting many other viruses, including HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA).

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ENZOLYTICS, INC.	-79.43%	12.13M
VERTEX PHARMACEUTICALS INCORPORATED	+9.99%	115B
REGENERON PHARMACEUTICALS, INC.	+12.01%	106B
BIONTECH SE	-3.07%	24.69B
ARGENX SE	-0.82%	21.97B
GENMAB A/S	-5.57%	19.27B
BEIGENE, LTD.	-6.90%	17.56B
WUXI APPTEC CO., LTD.	-39.36%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+5.82%	14.03B
SAREPTA THERAPEUTICS, INC.	+33.05%	12.13B

Bio Therapeutic Drugs

Enzolytics, Inc.

Equities

ENZC

US2941121079

Biotechnology & Medical Research

Enzolytics Inc. announced that it has received $0.25 million in funding

Latest news about Enzolytics, Inc.

Chart Enzolytics, Inc.

Company Profile

Sector Bio Therapeutic Drugs